Bp Plc (0HKP) Quote

Form 4 - Statement of changes in beneficial ownership of securities

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30...

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

– New 5-Year Clinical and Real-World Data Reinforce Biktarvy® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational...

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada® for PrEP – – If Approved, Lenacapavir Would be the First...

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

– RADIAN’s Five-Year, $25 Million Extension Will Increase Support for Local Organizations and Drive Progress to Help Turn the Tide on HIV Across the Region – – RADIAN Will Expand Geographic Focus...

Form 8-K - Current report

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company works to identify a successor...

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

- Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir - - Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development...

EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIH

EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA...

Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains

Honeywell (NASDAQ:HON) – Honeywell announced the acquisition of CAES Systems for $1.9 billion, focusing on expanding its aerospace and defense technology operations. Under the leadership of...